Friday, July 10, 2026

pharma · Early Childhood Caries · Acute Myeloid Leukemia

University of Hong

University of Hong is a pharma organization headquartered in CN. Primary therapeutic focus areas include Early Childhood Caries, Acute Myeloid Leukemia, Influenza Virus Infection, Smoking Cessation, Influenza. NovaPharma

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
42
Drugs
71
Patents
0
Clinical program

Atezolizumab

Phase 2 · small molecule · NSCLC Stage IIIB

Atezolizumab for NSCLC Stage IIIB is a Phase 2 program (small_molecule) at The University of Hong Kong with 1 ClinicalTrials.gov record(s).

Internal code ML40560

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
The University of Hong Kong
Phase
Phase 2
Modality
small_molecule
Indication
NSCLC Stage IIIB
Status
active
Trials
1